Monitor the company's next quarterly filing for any revenue or earnings deterioration that could further pressure the stock price. The reverse stock split path, if pursued, is a mechanical fix that does not address underlying business fundamentals — watch for any operational updates or strategic initiatives that could organically lift the stock above $1.00 before the cure period expires.
Price Chart
Executive Summary
Accendra Health received a delisting notice from the NYSE on October 6, 2026, because its average closing stock price fell below $1.00 per share over 30 consecutive trading days. The company has a six-month cure period and intends to consider alternatives including a reverse stock split, subject to shareholder approval at the May 2027 annual meeting. The stock continues to trade normally during the cure period, but the notice signals severe price distress and potential delisting risk if compliance is not regained.
Key Facts
- NYSE notice received October 6, 2026 for non-compliance with Section 802.01C (minimum $1.00 average closing price over 30 consecutive trading days)
- Company has a six-month cure period from receipt of notice to regain compliance
- Cure alternatives include a reverse stock split, requiring stockholder approval at the next annual meeting anticipated in May 2027
- Stock continues to trade on NYSE during the cure period subject to other continued listing requirements
- Company must notify NYSE of intent to cure within 10 business days of the notice
Financial Impact
No financial figures provided in the filing. The delisting notice itself does not specify any dollar amounts, but the sub-$1.00 stock price indicates severe market value erosion.
Risk Factors
- Failure to regain compliance within six months could lead to NYSE delisting, severely reducing liquidity and institutional ownership
- A reverse stock split, while curing the price deficiency, does not address the fundamental business challenges that caused the stock to trade below $1.00
- Shareholder approval for a reverse split is not guaranteed and may face opposition
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115043 |
| Document: ach-ex99d1.htm | 0001104659-26-115043 |
| Document: 0001104659-26-115043-index-headers.html | 0001104659-26-115043 |
| Document: 0001104659-26-115043-index.html | 0001104659-26-115043 |
| Document: 0001104659-26-115043.txt | 0001104659-26-115043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $0.3905 $0.2202 | ▲ +43.61% | ▲ +42.12% | $0.2029 (+48.04%) |
Oct 7, 2026 19d ago | SC 13G | $0.4729 $0.3128 | ▼ −33.85% | ▼ −32.87% | $0.2029 (−57.09%) |
Sep 17, 2026 5w ago | 8-K | $1.03 $0.7332 | ▼ −28.82% | ▼ −29.42% | $0.2029 (−80.30%) |
Aug 17, 2026 10w ago | 8-K | $1.07 $1.16 | ▲ +8.41% | ▲ +9.60% | $0.2029 (−81.04%) |
Aug 16, 2026 10w ago | Institutional Cluster | $1.07 $1.16 | ▲ +8.41% | ▲ +9.60% | $0.2029 (−81.04%) |
Aug 10, 2026 11w ago | 8-K | $1.26 $1.13 | ▼ −10.32% | ▼ −9.91% | $0.2029 (−83.90%) |
Aug 10, 2026 11w ago | 8-K | $1.40 $1.07 | ▲ +23.57% | ▲ +23.52% | $0.2029 (+85.51%) |
Aug 10, 2026 11w ago | 8-K | $1.40 $1.07 | ▼ −23.57% | ▼ −23.52% | $0.2029 (−85.51%) |
Jul 27, 2026 13w ago | EFFECT | $3.22 $3.41 | ▲ +5.90% | ▲ +3.39% | $0.2029 (−93.70%) |
Jun 25, 2026 17w ago | 8-K | $3.34 $3.59 | ▲ +7.49% | ▲ +5.32% | $0.2029 (−93.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers